AGM Information • May 25, 2023
AGM Information
Open in ViewerOpens in native device viewer
CAP Business Center Zone Industrielle des Hauts-Sarts Rue d'Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège)
On 25 May 2023, the ordinary general shareholders' meeting of MDxHealth SA (the "Company") is held at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium.
The ordinary general shareholders' meeting is opened at 3.00 p.m. by Ahok BV, represented by Mr. Koen Hoffman, independent director and chair of the board of directors (the "Chair").
The Chair notes that, in accordance with applicable law, French is the applicable working language for the meeting.
In accordance with the Company's articles of association, the Chair of the meeting designates Mr. Jean-Michaël Scelso as secretary of the meeting.
In view of the limited number of people present at the meeting, no tellers are appointed.
The Chair, together with the secretary, constitute the bureau of the general shareholders' meeting.
The Chair makes the following declarations with respect to the convening and composition of the meeting.
The Chair states that the meeting was convened with the following agenda and proposed resolutions:
Submission of, and discussion on, (a) the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022, (b) the report of the statutory auditor on the (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022, and (c) the report of the statutory auditor on the consolidated financial statements of the Company for the financial year ended on 31 December 2022.
Submission of, discussion on, and approval of the annual (non-consolidated) statutory financial statements for the financial year ended on 31 December 2022, and approval of the allocation of the result as proposed by the board of directors.
Proposed resolution: The general shareholders' meeting resolves to approve the annual (nonconsolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022 and to approve the allocation of the annual result as proposed by the board of directors.
Submission of, and discussion on, the consolidated financial statements of the Company for the financial year ended on 31 December 2022.
Discharge from liability of the directors for the exercise of their mandates during the financial year ended on 31 December 2022.
Proposed resolution: The general shareholders' meeting resolves to grant discharge from liability to each of the directors who was in office during the financial year ended on 31 December 2022, for the performance of its, his or her mandate during that financial year.
Discharge from liability of the statutory auditor for the exercise of its mandate during the financial year ended on 31 December 2022.
Proposed resolution: The general shareholders' meeting resolves to grant discharge from liability to the statutory auditor which was in office during the financial year ended on 31 December 2022, for the performance of its mandate during that financial year.
Submission of, discussion on, and approval of the remuneration report prepared by the nomination and remuneration committee and approved by the board of directors, and included in the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022.
Proposed resolution: The general shareholders' meeting resolves to approve the remuneration report included in the combined annual report of the board of directors on the consolidated and (nonconsolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022.
Taking into account the recommendation of the nomination and remuneration committee, the board of directors recommends that (a) Hilde Windels BV, represented by Hilde Windels as permanent representative, (b) Regine Slagmulder BV, represented by Regine Slagmulder as permanent representative, and (c) Eric Bednarski, be re-appointed as directors of the Company, each for a term of two years, and (d) Michael K. McGarrity be re-appointed as director of the Company for a term of three years.
For further information regarding these proposed directors, reference is made to the corporate governance statement included in the the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022.
Based on information made available by respectively Hilde Windels BV, represented by Hilde Windels as permanent representative, and Regine Slagmulder BV, represented by Regine Slagmulder as permanent representative, it appears that respectively each of Hilde Windels BV and Hilde Windels, and each of Regine Slagmulder BV and Regine Slagmulder, satisfy the applicable requirements in order to be nominated as independent directors in accordance with article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code.
Note: If the proposed resolutions set out in point 7 are approved by the general shareholders' meeting, the Company's board of directors will be composed of (1) Michael K. McGarrity, chief executive officer (CEO), executive director and managing director (until 2026), (2) Ahok BV, represented by Koen Hoffman, independent director and chair of the board of directors (until 2024), (3) Donnie M. Hardison JR, independent director (until 2025), (4) Hilde Windels BV, represented by Hilde Windels, independent director (until 2025), (5) Qaly-Co BV, represented by Lieve Verplancke, independent director (until 2024), (6) Valiance Advisors LLP, represented by Jan Pensaert, non-executive director (until 2024), (7) Regine Slagmulder BV, represented by Regine Slagmulder, independent director (until 2025), and (9) Eric Bednarski, non-executive director (until 2025).
Taking into account the recommendation and preference of the audit committee, the board of directors recommends that BDO Réviseurs d'Entreprises SRL, represented by Bert Kegels as permanent representative, be re-appointed as statutory auditor of the Company for a term of three years up to and including the closing of the ordinary general shareholders' meeting to be held in 2026 which will have decided upon the financial statements for the financial year ended on 31 December 2025, subject to, and in accordance with, the provisions of article 3:61 of the Belgian Companies and Associations Code and Regulation (EU) No. 537/2014 of the European Parliament and of the Council of 16 April 2014 on specific requirements regarding statutory audit of public-interest entities and repealing Commission Decision 2005/909/EC.
Proposed resolution: Taking into account the recommendation of the board of directors upon recommendation and preference of the audit committee, the general shareholders' meeting resolves to re-appoint BDO Réviseurs d'Entreprises SRL, represented by Bert Kegels as permanent representative, as statutory auditor of the Company for a term of three years up to and including the closing of the ordinary general shareholders' meeting to be held in 2026 which will have decided upon the financial statements for the financial year ended on 31 December 2025, subject to, and in accordance with, the provisions of article 3:61 of the Belgian Companies and Associations Code and Regulation (EU) No. 537/2014 of the European Parliament and of the Council of 16 April 2014 on specific requirements regarding statutory audit of public-interest entities and repealing Commission Decision 2005/909/EC. For the duration of its mandate, the annual remuneration of the statutory auditor of the Company shall be EUR 260,000.00 (excluding VAT, taxes and expenses, as applicable) for the audit of the consolidated accounts of the group and the audit of the (non-consolidated) statutory financial statements of the Company. These fees are subject to a yearly indexation based on the standard index.
On 2 August 2022, the Company entered into a loan and security agreement with Innovatus Life Sciences Lending Fund I, LP, pursuant to which Innovatus Life Sciences Lending Fund I, LP agreed to provide a loan facility for up to USD 70,000,000.00, which can be drawn in multiple tranches. Sections 2.2(c), 7.2, 7.3 and 8.2 of the loan and security agreement allow Innovatus Life Sciences Lending Fund I, LP to terminate the loan and security agreement and demand immediate (re)payment of all amounts outstanding under the loan and security agreement in case of a change of control over the Company or any subsidiaries of the Company.
Proposed resolution: The general shareholders' meeting resolves to approve and ratify, in accordance with article 7:151 of the Belgian Companies and Associations Code, all clauses in the loan and security agreement entered into by the Company and Innovatus Life Sciences Lending Fund I, LP (including, but not limited to, Sections 2.2(c), 7.2, 7.3 and 8.2) that are applicable at the time a change of control occurs and which fall or could be considered to fall within the scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company's assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it). The general shareholders' meeting also grants a special power of attorney to each Director of the Company, the Chief Financial Officer and the Executive Vice President of Corporate Development and General Counsel (each a "Proxy Holder"), each Proxy Holder acting individually and with the right of substitution, to complete the formalities required by article 7:151 of the Belgian Companies and Associations Code with regard to this resolution, including, but not limited to, the execution of all documents and forms required for the publication of this resolution in the annexes to the Belgian Official Gazette.
The Chair declares that, according to article 7:128 of the Belgian Companies and Associations Code, the notices convening this general shareholders' meeting, containing amongst others, the agenda, the proposed resolutions and other information required by the Belgian Companies and Associations Code, have been published thirty (30) calendar days prior this meeting in:
Copies of the publications are submitted to the bureau and initialled by the members of the bureau. These will be kept in the files of the Company together with the minutes of this meeting.
On 25 April 2023, the Company also issued a press release on its website, announcing the convening of this general shareholders' meeting.
The Chair declares that, according to article 7:128 and 7:132 of the Belgian Companies and Associations Code, the notices convening the ordinary general shareholders' meeting have also been sent by email at least thirty (30) calendar days before the date of the meeting to the directors of the Company, the statutory auditor of the Company, the holders of registered shares issued by the Company and the holders of subscription rights.
Proofs of the convening notices are being submitted as evidence to the meeting, for consultation. The proofs will be attached to these minutes as Annex A and kept in the Company's files together with the minutes of this meeting.
In addition, as from 25 April 2023, the following documentation has been made available to the public and the holders of securities issued by the Company on the Company's website (www.mdxhealth.com) (in addition to any documentation related to the extraordinary general shareholders' meeting also to be held on 25 May 2023):
The proofs will be kept in the files of the Company together with the minutes of this meeting. The Company has not received any requests, in accordance with the Belgian Companies and Associations Code, from shareholders who alone or together with other shareholders hold at least 3% of the share capital to put additional items on the agenda of the ordinary general shareholders' meeting and/or to table draft resolutions in relation to items that have been or were to be included in the agenda.
The registration date of the ordinary general shareholders' meeting was Thursday, 11 May 2023, at midnight (12.00 a.m., Belgian Time) (the "Registration Date"). In accordance with the applicable legislation, only persons owning securities issued by the Company on the aforementioned Registration Date shall be entitled to participate and, as the case may be, vote at the general ordinary shareholders' meeting.
A register has been prepared in which, for each shareholder having notified its intention to participate to the meeting, the following information was included: (i) the name of the shareholder and its address or registered office, (ii) the number of shares owned on the Registration Date, and (iii) a description of the documents which indicate the holding of the shares on the Registration Date. This register is attached to these minutes as Annex B.
In addition, an attendance list has been prepared indicating (i) the identity of the shareholders that are present or represented to the meeting, (ii) the domicile or registered office of such shareholders, (iii) if applicable, the identity of the proxy-holder of such shareholders, and (iv) the number of shares that the shareholders held on the Registration Date and with which such shareholders are participating in the voting. The attendance list also indicates the directors and the statutory auditor that are present or represented at the meeting, as well as the holders of subscription rights previously issued by the Company present or represented at the meeting. The attendance list has been signed the proxy holders of, or (as the case may be) the Chair on behalf of, the shareholders, directors, statutory auditor and holders of subscription rights who are represented at the meeting. The attendance list is attached to these minutes as Annex C. The proxies will also be kept with the attendance list in the files of the Company together with the minutes of this meeting.
In addition, a separate list has been prepared for the shareholders that have validly submitted their votes by mail in accordance with article 39 of the Company's articles of associations and the modalities laid out in the convening notice to this ordinary general shareholders' meeting, in which the following information was included: (i) the identity of the shareholders that have validly submitted votes by mail, (ii) the domicile or registered office of such shareholders, and (iii) the number of shares with which such shareholders are participating in the voting. The list of voting by mail forms is attached to these minutes as Annex D.
The aforementioned lists and the register are submitted to the bureau and are subsequently closed, initialled and signed by the members of the bureau. The lists as well as the register will be kept in the files of the Company together with the minutes of this meeting.
All holders of securities issued by the Company that are present or represented at the meeting included in the register and in the aforementioned lists have complied with the formalities in order to be admitted to the ordinary general shareholders' meeting in accordance with the Company's articles of association and the Belgian Companies and Associations Code and as set out in the convening notice.
The certificates which have been filed with respect to dematerialised shares, the letters submitted with respect to registered shares and the proxies that have been submitted by the shareholders, will be kept in the files of the Company together with the minutes of this meeting.
The Chair indicates that the Company's share capital amounts to EUR 163,471,629.58 and is represented by 270,380,936 shares, without nominal value, each representing the same fraction of the Company's share capital. Based on the aforementioned attendance list and the verification of the admission to the ordinary general shareholders' meeting, it appears that 119.823.899 shares in total or 44.32% of the outstanding and existing shares are present or represented at the meeting.
The Chair declares that, according to article 25/1 of the Belgian Act of 2 May 2007 on the disclosure of significant shareholdings in issuers whose securities are admitted to trading on a regulated market and containing various provisions, as amended from time to time (the "Belgian Transparency Act"), no person can participate in the voting of a general shareholders' meeting for more voting rights than those attached to the securities with respect to which such person has filed a notification at least twenty (20) days prior to the date of the meeting, in accordance with articles 6 and 7 of the Belgian Transparency Act.
Pursuant to article 14 of the Company's articles of association, the relevant thresholds for a notification are fixed at three percent (3%), five percent (5%) and any further multiple of five percent (5%) of the outstanding voting rights.
For all of the shareholders present or represented, it is confirmed that they can participate in the vote with all the shares submitted for voting.
The Chair declares that, according to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to participate to the ordinary general shareholders' meeting, but with an advisory vote only.
According to the Belgian Companies and Associations Code, there is no quorum requirement for the voting on the respective items referred to in the aforementioned agenda of the ordinary general shareholders' meeting.
Each of the proposed resolutions under the respective items included in the aforementioned agenda shall be passed if it is approved by a simple majority of the votes validly casted.
Each share is entitled to one vote.
A number of persons attend the meeting, such as certain members of the staff of the Company and third parties engaged by the Company to provide services in connection with the general shareholders' meeting. Upon proposal of the Chair, the meeting allows such persons to attend. The aforementioned persons have signed the attendance list regarding persons that are not a shareholder or that are a shareholder but have not complied with the formalities to be admitted to the meeting
The aforementioned statements by the Chair are verified and approved by all members of the ordinary general shareholders' meeting. Subsequently, the ordinary general shareholders' meeting determines and confirms that it has been validly convened and is validly constituted, and that it is authorized to deliberate and vote on the items on the agenda of the meeting.
Upon proposal by the Chair, the meeting begins with the deliberation on the items on the agenda.
The Chair summarises the items of the agenda of the meeting.
The Chair submits to the meeting the following documentation that has been mentioned in the first items on the agenda of the meeting:
The Chair states that these documents have been made available to the directors, the statutory auditor and the holders of securities issued by the Company in accordance with the Company's articles of association and the Belgian Companies and Associations Code. The Chair also states that these documents have been made available to the holders of securities issued by the Company and to the public on the Company's website. The documents concerned will be kept in the files of the Company together with the minutes of this meeting.
The meeting takes note of the fact that this documentation has been submitted. The meeting releases the Chair from reading the documentation that has been submitted.
Each holder of securities issued by the Company had the right to ask questions to the directors and the statutory auditor related to items on the agenda of a general shareholders' meetings. The Chair informs the meeting that no holders of securities have submitted written questions prior to the meeting in accordance with article 7:139 of the Belgian Companies and Associations Code and the modalities laid out in the convening notice.
Furthermore, after the discussion, no question is asked by the meeting in accordance with article 7:139 of the Belgian Companies and Associations Code, with respect to the documents that have been submitted to the meeting and with respect to the items of the agenda of the meeting.
Subsequently, upon proposal of the Chair, the meeting proceeds with the deliberation and voting with respect to each of the items on the agenda.
The items on the agenda are separately voted upon.
This agenda item relates to the submission of, and discussion on, (a) the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022, (b) the report of the statutory auditor on the (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022, and (c) the report of the statutory auditor on the consolidated financial statements of the Company for the financial year ended on 31 December 2022.
The Chair requires that a copy of such documents be attached to these minutes as Annex E.
This agenda item requires no further resolution.
This agenda item relates to the submission of, discussion on, and approval of the annual (nonconsolidated) statutory financial statements for the financial year ended on 31 December 2022, and approval of the allocation of the result as proposed by the board of directors.
The Chair requires that a copy of such document be attached to these minutes as Annex F.
The following resolution is passed with a majority of 99.59%:
The general shareholders' meeting resolves to approve the annual (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022 and to approve the allocation of the annual result as proposed by the board of directors.
Vote: This resolution is passed as follows:
This agenda item relates to the submission of, and discussion on, the consolidated financial statements of the Company for the financial year ended on 31 December 2022.
The Chair requires that a copy of such document be attached to these minutes as Annex G.
This agenda item requires no further resolution.
This agenda item relates to the discharge from liability of the directors for the exercise of their mandates during the financial year ended on 31 December 2022.
The following resolution is passed with a majority of 98.07%:
The general shareholders' meeting resolves to grant discharge from liability to each of the directors who was in office during the financial year ended on 31 December 2022, for the performance of its, his or her mandate during that financial year.
Vote: This resolution is passed as follows:
This agenda item relates to the discharge from liability of the statutory auditor for the exercise of its mandate during the financial year ended on 31 December 2022.
The following resolution is passed with a majority of 99.33%:
The general shareholders' meeting resolves to grant discharge from liability to the statutory auditor which was in office during the financial year ended on 31 December 2022, for the performance of its mandate during that financial year.
Vote: This resolution is passed as follows:
This agenda item relates to the submission of, discussion on, and approval of the remuneration report prepared by the nomination and remuneration committee and approved by the board of directors, and included in the combined annual report of the board of directors on the consolidated and (nonconsolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022.
The following resolution is passed with a majority of 57.94%:
The general shareholders' meeting resolves to approve the remuneration report included in the combined annual report of the board of directors on the consolidated and (nonconsolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022.
Vote: This resolution is passed as follows:
This agenda item relates to the re-appointment of directors.
Taking into account the recommendation of the nomination and remuneration committee, the board of directors recommends that (a) Hilde Windels BV, represented by Hilde Windels as permanent representative, (b) Regine Slagmulder BV, represented by Regine Slagmulder as permanent representative, and (c) Eric Bednarski, be re-appointed as directors of the Company, each for a term of two years, and (d) Michael K. McGarrity be re-appointed as director of the Company for a term of three years.
For further information regarding these proposed directors, reference is made to the corporate governance statement included in the the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022.
Based on information made available by respectively Hilde Windels BV, represented by Hilde Windels as permanent representative, and Regine Slagmulder BV, represented by Regine Slagmulder as permanent representative, it appears that respectively each of Hilde Windels BV and Hilde Windels, and each of Regine Slagmulder BV and Regine Slagmulder, satisfy the applicable requirements in order to be nominated as independent directors in accordance with article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code.
The following resolutions are passed:
(a) The general shareholders' meeting resolves to re-appoint Hilde Windels BV, represented by Hilde Windels as permanent representative, as independent director of the Company within the meaning of article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code, for a term of two years, up to and including the closing of the ordinary general shareholders' meeting to be held in 2025 which will have decided upon the financial statements for the financial year ended on 31 December 2024. The remuneration of the director is as set out in the Company's remuneration policy, as approved from time to time by the general shareholders' meeting, and (subject to the provisions of the remuneration policy) as decided by the special general shareholders' meeting held on 30 July 2020 and the ordinary general shareholders' meeting held on 27 May 2021.
Vote: This resolution is passed with a majority of 99.67% as follows:
Vote: This resolution is passed with a majority of 99.66% as follows:
Vote: This resolution is passed with a majority of 94.96% as follows:
Vote: This resolution is passed with a majority of 99.67% as follows:
As a result of the approval of the resolutions set out in point 7, the Company's board of directors is now composed of (1) Michael K. McGarrity, chief executive officer (CEO), executive director and managing director (until 2026), (2) Ahok BV, represented by Koen Hoffman, independent director and chair of the board of directors (until 2024), (3) Donnie M. Hardison JR, independent director (until 2025), (4) Hilde Windels BV, represented by Hilde Windels, independent director (until 2025), (5) Qaly-Co BV, represented by Lieve Verplancke, independent director (until 2024), (6) Valiance Advisors LLP, represented by Jan Pensaert, non-executive director (until 2024), (7) Regine Slagmulder BV, represented by Regine Slagmulder, independent director (until 2025), and (8) Eric Bednarski, nonexecutive director (until 2025).
This agenda item relates to the re-appointment of the statutory auditor.
Taking into account the recommendation and preference of the audit committee, the board of directors recommends that BDO Réviseurs d'Entreprises SRL, represented by Bert Kegels as permanent representative, be re-appointed as statutory auditor of the Company for a term of three years up to and including the closing of the ordinary general shareholders' meeting to be held in 2026 which will have decided upon the financial statements for the financial year ended on 31 December 2025, subject to, and in accordance with, the provisions of article 3:61 of the Belgian Companies and Associations Code and Regulation (EU) No. 537/2014 of the European Parliament and of the Council of 16 April 2014 on specific requirements regarding statutory audit of public-interest entities and repealing Commission Decision 2005/909/EC.
The following resolution is passed with a majority of 99.67%:
Taking into account the recommendation of the board of directors upon recommendation and preference of the audit committee, the general shareholders' meeting resolves to re-appoint BDO Réviseurs d'Entreprises SRL, represented by Bert Kegels as permanent representative, as statutory auditor of the Company for a term of three years up to and including the closing of the ordinary general shareholders' meeting to be held in 2026 which will have decided upon the financial statements for the financial year ended on 31 December 2025, subject to, and in accordance with, the provisions of article 3:61 of the Belgian Companies and Associations Code and Regulation (EU) No. 537/2014 of the European Parliament and of the Council of 16 April 2014 on specific requirements regarding statutory audit of public-interest entities and repealing Commission Decision 2005/909/EC. For the duration of its mandate, the annual remuneration of the statutory auditor of the Company shall be EUR 260,000.00 (excluding VAT, taxes and expenses, as applicable) for the audit of the consolidated accounts of the group and the audit of the (non-consolidated) statutory financial statements of the Company. These fees are subject to a yearly indexation based on the standard index.
Vote: This resolution is passed as follows:
This agenda item relates to the approval in accordance with article 7:151 of the Belgian Companies and Associations Code with respect to the loan and security agreement entered into on 2 August 2022 by the Company and Innovatus Life Sciences Lending Fund I, LP, pursuant to which Innovatus Life Sciences Lending Fund I, LP agreed to provide a loan facility for up to USD 70,000,000.00, which can be drawn in multiple tranches. Sections 2.2(c), 7.2, 7.3 and 8.2 of the loan and security agreement allow Innovatus Life Sciences Lending Fund I, LP to terminate the loan and security agreement and demand immediate (re)payment of all amounts outstanding under the loan and security agreement in case of a change of control over the Company or any subsidiaries of the Company.
The following resolution is passed with a majority of 99.47%:
The general shareholders' meeting resolves to approve and ratify, in accordance with article 7:151 of the Belgian Companies and Associations Code, all clauses in the loan and security agreement entered into by the Company and Innovatus Life Sciences Lending Fund I, LP (including, but not limited to, Sections 2.2(c), 7.2, 7.3 and 8.2) that are applicable at the time a change of control occurs and which fall or could be considered to fall within the scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company's assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it). The general shareholders' meeting also grants a special power of attorney to each Director of the Company, the Chief Financial Officer and the Executive Vice President of Corporate Development and General Counsel (each a "Proxy Holder"), each Proxy Holder acting individually and with the right of substitution, to complete the formalities required by article 7:151 of the Belgian Companies and Associations Code with regard to this resolution, including, but not limited to, the execution of all documents and forms required for the publication of this resolution in the annexes to the Belgian Official Gazette.
Vote: This resolution is passed as follows:
* * *
There being no further business and since no further items were raised, the meeting is adjourned by the Chair at 3:30 p.m.
These minutes are signed in three original copies by all members of the bureau.
By: /s/ Koen Hoffman By: /s/ Jean-Michaël Scelso
Ahok BV represented by Mr. Koen Hoffman Chair
Mr. Jean-Michaël Scelso Secretary
COPY OF (A) THE COMBINED ANNUAL REPORT OF THE BOARD OF DIRECTORS ON THE CONSOLIDATED AND (NON-CONSOLIDATED) STATUTORY FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2022, (B) THE REPORT OF THE STATUTORY AUDITOR ON THE (NON-CONSOLIDATED) STATUTORY FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2022, AND (C) THE REPORT OF THE STATUTORY AUDITOR ON THE CONSOLIDATED FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2022
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.